DE60322509D1 - Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung - Google Patents

Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Info

Publication number
DE60322509D1
DE60322509D1 DE60322509T DE60322509T DE60322509D1 DE 60322509 D1 DE60322509 D1 DE 60322509D1 DE 60322509 T DE60322509 T DE 60322509T DE 60322509 T DE60322509 T DE 60322509T DE 60322509 D1 DE60322509 D1 DE 60322509D1
Authority
DE
Germany
Prior art keywords
igfbp
antisense oligonucleotides
bis
specific antisense
oligonucleotides inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322509T
Other languages
English (en)
Inventor
Martin Gleave
Maxim Signaevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60322509D1 publication Critical patent/DE60322509D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60322509T 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung Expired - Lifetime DE60322509D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Publications (1)

Publication Number Publication Date
DE60322509D1 true DE60322509D1 (de) 2008-09-11

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322509T Expired - Lifetime DE60322509D1 (de) 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Country Status (15)

Country Link
US (11) US20030158143A1 (de)
EP (1) EP1465995B1 (de)
JP (1) JP4491240B2 (de)
KR (2) KR101265180B1 (de)
AT (1) ATE402999T1 (de)
AU (1) AU2003237616B2 (de)
CA (1) CA2469685C (de)
DE (1) DE60322509D1 (de)
DK (1) DK1465995T3 (de)
ES (1) ES2307942T3 (de)
HU (1) HU229452B1 (de)
IL (2) IL162540A0 (de)
NO (1) NO333017B1 (de)
NZ (1) NZ533126A (de)
WO (1) WO2003062421A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
JP4785252B2 (ja) 1999-02-26 2011-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｔｒｐｍ−２アンチセンス療法
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2003237616B2 (en) * 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
AU2003258425B2 (en) 2002-08-21 2008-02-14 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
JP4717633B2 (ja) 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするＲＮＡｉプローブ
EP1560933A4 (de) * 2002-11-14 2007-11-21 Wyeth Corp Verfahren und zusammensetzungen zur behandlung neurologischer erkrankungen
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
ES2456017T3 (es) * 2004-11-23 2014-04-21 The University Of British Columbia Tratamiento del cáncer con una combinación de un agente que perturba la ruta de señalización de EGF y un oligonucleótido que reduce los niveles de clusterina
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
US8044179B2 (en) * 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CA2703795A1 (en) * 2006-10-27 2008-05-02 Mount Sinai Hospital Endometrial phase or endometrial cancer biomarkers
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
KR101821343B1 (ko) 2010-03-01 2018-01-23 타우 쎄라퓨틱스 엘엘씨 암 진단 및 영상화
EA201391725A1 (ru) * 2011-05-19 2014-05-30 Тева Фармасьютикал Индастриз Лтд. Способ лечения немелкоклеточного рака легкого
WO2013039859A1 (en) 2011-09-12 2013-03-21 Gray Lloyd S Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
EP3362563A1 (de) 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy-nukleinsäuren für liposomale formulierung
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
KR20190053905A (ko) 2016-09-16 2019-05-20 바이오-패쓰 홀딩스 인크. 리포솜 안티센스 올리고뉴클레오타이드와의 병용 요법
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
SG11201909336VA (en) 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for stat3 inhibition
IL270180B (en) 2017-04-26 2022-06-01 Cavion Inc Methods to improve memory and cognition and to treat memory and cognition disorders
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
EP3860571A4 (de) 2018-10-03 2022-06-29 Cavion, Inc. Behandlung von essentiellem tremor unter verwendung von (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluorethoxy)pyridin-2-yl)ethyl)acetamid

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003471A1 (en) 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
IE913035A1 (en) 1990-08-28 1992-03-11 Chiron Corp Genetic material encoding new insulin-like growth factor¹binding protein (igfbp-5)
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
ATE234919T1 (de) * 1993-12-23 2003-04-15 Biognostik Ges Antisense nukleinsäuren zur vorbeugung und behandlung von beschwerden in welchen die exprimierung von c-erbb-2 eine rolle spielt
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DK0882061T3 (da) * 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
CA2349721A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
JP4785252B2 (ja) 1999-02-26 2011-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｔｒｐｍ−２アンチセンス療法
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
IL146565A0 (en) * 1999-07-19 2002-07-25 Univ British Columbia A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
EP1242050A4 (de) 1999-12-21 2004-05-26 Univ Yale Förderung der angiogenese durch survivin
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
KR100823120B1 (ko) * 2000-09-14 2008-04-18 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암 및 기타 내분비계 암 치료용 안티센스인슐린유사성장인자 결합단백질-2-올리고디옥시뉴클레오티드
EP1873259B1 (de) * 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Durch kleine 21nt- und 22nt-RNAs vermittelte RNA-Interferenz
US20030124513A1 (en) * 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
WO2003035843A2 (en) 2001-10-25 2003-05-01 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
AU2003237616B2 (en) * 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
JP2005530804A (ja) * 2002-05-14 2005-10-13 ベイラー　カレッジ　オブ　メディスン Ｈｅｒ２発現の小分子阻害剤
JP4717633B2 (ja) 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするＲＮＡｉプローブ
AU2003258425B2 (en) 2002-08-21 2008-02-14 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
KR20120107456A (ko) * 2009-07-30 2012-10-02 안티센스 파마 게엠베하 화학요법제와 티지에프-베타 시스템의 억제제의 조합

Also Published As

Publication number Publication date
JP2005514948A (ja) 2005-05-26
KR101265180B1 (ko) 2013-05-29
JP4491240B2 (ja) 2010-06-30
HUP0402543A2 (hu) 2005-03-29
ES2307942T3 (es) 2008-12-01
US20080261912A1 (en) 2008-10-23
US9101646B2 (en) 2015-08-11
EP1465995B1 (de) 2008-07-30
KR20040085150A (ko) 2004-10-07
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
IL162540A (en) 2011-06-30
CA2469685C (en) 2013-03-12
US20110196019A1 (en) 2011-08-11
NZ533126A (en) 2006-04-28
IL162540A0 (en) 2005-11-20
US20160002630A1 (en) 2016-01-07
US20120220646A1 (en) 2012-08-30
US8470796B2 (en) 2013-06-25
US20110190382A1 (en) 2011-08-04
DK1465995T3 (da) 2008-10-20
EP1465995A1 (de) 2004-10-13
KR101166214B1 (ko) 2012-07-16
ATE402999T1 (de) 2008-08-15
US8252765B2 (en) 2012-08-28
HU229452B1 (en) 2013-12-30
US7928082B2 (en) 2011-04-19
US8580761B2 (en) 2013-11-12
US7973017B2 (en) 2011-07-05
CA2469685A1 (en) 2003-07-31
US20130303592A1 (en) 2013-11-14
US20130096180A1 (en) 2013-04-18
US8835401B2 (en) 2014-09-16
US20120077861A1 (en) 2012-03-29
US20100267808A1 (en) 2010-10-21
NO20043401L (no) 2004-10-13
US8541390B2 (en) 2013-09-24
HUP0402543A3 (en) 2012-09-28
US20030158143A1 (en) 2003-08-21
AU2003237616B2 (en) 2007-07-05
US20060122141A1 (en) 2006-06-08
NO333017B1 (no) 2013-02-18
WO2003062421A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DE60322509D1 (de) Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
IL197159A (en) Two-stranded rna molecules that complement a sense or antisense strand of a human encoding igfbp-2 and igfbp-5, preparations containing them and their uses
ATE327757T1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
HK1089501A1 (en) Self-inflating cushion and article of shoe including same
TW200612918A (en) Lonidamine analogs
HK1095749A1 (en) Novel use of peptide compounds for in production of pharmacenticals for treating central neuropathic pain
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
HUP0301179A2 (hu) Módosított VIII-as faktor
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE518531T1 (de) Alpha-humulene zur verwendung bei der prophylaxe oder behandlung der entzündlichen schmerzen und des ödems
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
BG105779A (en) Human antibiotic proteins
DE602004022921D1 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
CA104143S (en) Brush
EP1610807A4 (de) Verwendung von wiederholungssequenz-protein-polymeren in körperpflegezusammensetzungen
ATE420074T1 (de) Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
AU309683S (en) Massaging belt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition